Skip to main content

Advertisement

SpringerLink
Log in

Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis?

  • Inflammatory Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

To evaluate the efficacy of suppressing a recurrence of Toxoplasma retinochoroiditis after treatment with atovaquone.

Methods

Retrospective, nonrandomized, clinical trial. Forty-one immunocompetent patients were treated for Toxoplasma retinochoroiditis with atovaquone between 1999 and 2006. The diagnosis was based on clinical signs alone. Atovaquone was given 750 mg two to three times daily together with oral steroids. Lesion location, time interval until recurrence, visual function, and adverse events were recorded.

Results

Forty-two eyes of 41 patients were treated with atovaquone for Toxoplasma retinochoroiditis. Side-effects were usually mild and only one patient stopped therapy with atovaquone because of nausea. Reactivation of retinochoroiditis occurred in 18 patients (44%) during a time interval of 3–70 months.

Conclusions

The therapy of Toxoplasma retinochoroiditis with atovaquone is well tolerated. Our data suggests that therapy with atovaquone has the potential to prolong the time to recurrence of Toxoplasma retinochoroiditis. A prospective randomized comparative long-term clinical trial would be necessary to confirm our data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Wilder HC (1952) Toxoplasma chorioretinitis in adults. Arch Ophthalmol 48:127–136

    CAS  Google Scholar 

  2. Rothova A, Meenken C, Buitenhuis HJ (1993) Therapy for ocular toxoplasmosis. Am J Ophthalmol 115:517–523

    CAS  PubMed  Google Scholar 

  3. Acers TE (1964) Toxoplasmic retinochoroiditis: a double-blind therapeutic study. Arch Ophthalmol 71:58–62

    CAS  PubMed  Google Scholar 

  4. Stanford MR, See SE, Jones LV (2003) Antibiotics for toxoplasmic retinochoroiditis: an evidence-based systemic review. Ophthalmology 110:926–931

    Article  PubMed  Google Scholar 

  5. Holland GN, O’Connor G, Belfort R Jr, Remington JS (2003) Ocular toxoplasmosis: a global reassessment. Part I: Epidemiology and course of disease. Am J Ophthalmol 136:973–988

    Article  PubMed  Google Scholar 

  6. Garweg JG, Scherrer JN, Halberstad M (2008) Recurrence characteristics in European patients with ocular toxoplasmosis. BJO 92(9):1253–1256

    Article  CAS  Google Scholar 

  7. Bosch-Driessen L, Berendschot T, Ongkosuwito J, Rothova A (2002) Ocular toxoplasmosis—clinical features and prognosis of 154 patients. Ophthalmology 109(5):869–878

    Article  PubMed  Google Scholar 

  8. Huskinson-Mark J, Araujo FG, Remington JS (1991) Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis 164:170–177

    CAS  PubMed  Google Scholar 

  9. Rothova A, Bosch-Driessen E, van Loon NH, Treffers WF (1998) Azithromycin for ocular toxoplasmosis. Br J Ophthalmol 82:1306–1308

    Article  CAS  PubMed  Google Scholar 

  10. Gormley PD, Pavesio CE, Minnasian D, Lightman S (1998) Effects of drug therapy on toxoplasma cysts in an animal model of acute and chronic disease. Invest Ophthalmol Vis Sci 39:1171–1175

    CAS  PubMed  Google Scholar 

  11. Pearson PA, Piracha AR, Sen HA, Jaffe GJ (1999) Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients. Ophthalmology 106(1):148–153

    Article  CAS  PubMed  Google Scholar 

  12. Holland GN, O’Connor GR, Belfort R Jr, Remington JS (1996) Ocular infection and immunity. Mosby-Year Book, St. Louis, pp 1183–1223

    Google Scholar 

  13. Holland G, Crespi CM, Dam-van Loon N et al (2008) Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis. Am J Ophthalmol 145(6):1007–1013

    Article  PubMed  Google Scholar 

  14. Tugal-Tutkun I, Corum I, Ötük B, Urgancioglu M (2005) Active ocular toxoplasmosis in Turkish patients: a report on 109 cases. Int Ophthalmol 26:221–228

    Article  PubMed  Google Scholar 

  15. Rolan PE, Mercer AJ, Weatherley BC (1994) Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol 37:13–20

    CAS  PubMed  Google Scholar 

  16. Pleyer U, Torun N, Liesenfeld O (2007) Okuläre Toxoplasmose. Der Ophthalmologe 104:603–616

    Article  CAS  PubMed  Google Scholar 

  17. Bosch-Driessen EH, Rothova A (1998) Sense and nonsense of corticosteroid administration in the treatment of ocular toxoplasmosis. Br J Ophthalmol 82(8):858–860

    Article  CAS  PubMed  Google Scholar 

  18. Hofflin JM, Conley FK, Remington JS (1987) Murine model of intracerebral toxoplasmosis. J Infect Dis 155:550–556

    CAS  PubMed  Google Scholar 

  19. Durrani OM, Meeds CA, Murray PI (2004) Uveitis: a potentially blinding disease. Opththalmologica 218(4):223–236

    Article  CAS  Google Scholar 

  20. Krumpaszky HG, Klauß V, Kloske G (1992) Soziale Kosten von Sehbehinderung und Blindheit. Rehabilitationsangebot für die Betroffenen Klin Mbl Augenheilk 201:370–374

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University Hospital Düsseldorf, Düsseldorf, Germany

    Sibylle Winterhalter, Katja Severing, Johannes Stammen, Anna Karina Maier & Antonia Maria Joussen

  2. Department of Cardiovascular Surgery (Biometric Unit), University Hospital Düsseldorf, Düsseldorf, Germany

    Erhard Godehardt

  3. Department of Ophthalmology, University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany

    Sibylle Winterhalter

Authors
  1. Sibylle Winterhalter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katja Severing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johannes Stammen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna Karina Maier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Erhard Godehardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Antonia Maria Joussen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sibylle Winterhalter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Winterhalter, S., Severing, K., Stammen, J. et al. Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis?. Graefes Arch Clin Exp Ophthalmol 248, 1187–1192 (2010). https://doi.org/10.1007/s00417-010-1379-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-010-1379-9

Keywords

Search

Navigation